

3. An ophthalmic solution according to claim 1, further comprising one or more buffers.

4. An ophthalmic solution according to claim 1, comprising from 0.005% to 0.50% in weight of sodium hyaluronate and from 0.010% to 2.0% in weight of ^{said} poloxamer ~~407~~.

8. Use according to claim 6, wherein said ophthalmic solution contains sodium hyaluronate as viscosity enhancing agent.

Attached hereto is page 3 that presents a marked up version of the changes made to claims 3, 4 and 8 by this preliminary amendment. Page 3 is captioned "Version With Markings To Show Changes Made."

Respectfully submitted,

By: Clifford W. Browning
Clifford W. Browning
Reg. No. 32,201
Woodard, Emhardt, Naughton,
Moriarty & McNett
Bank One Center/Tower
111 Monument Circle, Suite 3700
Indianapolis, Indiana 46204-5137
(317) 634-3456

#143192

VERSION WITH MARKINGS TO SHOW CHANGES MADE

3. (Amended) An ophthalmic solution according to claim 1 [or 2], further comprising one or more buffers.

4. (Amended) An ophthalmic solution according to [any one of the preceding claims] claim 1, comprising from 0.005% to 0.50% in weight of sodium hyaluronate and from 0.010% to 2.0% in weight of poloxamer 407.

8. (Amended) Use according to claim 6 [or 7], wherein said ophthalmic solution contains sodium hyaluronate as viscosity enhancing agent.

Accepted for filing

A